$ cat ./records/gates-backed-world-mosquito-program-yogyakarta-rct-shows-77-dengu-2021.txt
Gates-Backed World Mosquito Program Yogyakarta RCT Shows 77% Dengue Reduction in New England Journal of Medicine
[RECORD.TXT] · cat --full
The Gates Foundation-supported World Mosquito Program published randomised controlled trial results in the New England Journal of Medicine in 2021 showing Wolbachia-carrying mosquito deployments in Yogyakarta, Indonesia reduced dengue incidence by 77.1 percent and hospitalisation by 86 percent in treated clusters versus controls. This was the first blinded RCT for any biological dengue intervention and provided the highest level of evidence for large-scale city-level Wolbachia deployment programmes.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Co-Funds WHO mRNA Technology Transfer Hub in South Africa
Next →
Gates Foundation Awards Oxitec $4.85 Million to Advance Self-Limiting Cattle Tick Program
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.